BioCentury
ARTICLE | Clinical News

Duexis ibuprofen/famotidine regulatory update

August 4, 2014 7:00 AM UTC

Horizon said it will “immediately accelerate its patient- and physician-focused commercial model to focus prescriptions through other channels,” work with other PBMs and “evaluate price increases.” According to the Red Book, the average wholesale price (AWP) of Vimovo increased 597% on Jan. 1, 2014, and the AWP of Duexis has gone up 473% since its launch in 2011. Each drug has a wholesale acquisition cost (WAC) of $799.20 for a 30-day supply. ...